What is Virbac SA?
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.
VRBCF · Verdict
Solid reward · moderate risk
VRBCF scores well on cash flow and profitability with no major weaknesses flagged in the model.
Based on 88% data coverage
VRBCF · Verdict
9% free-cash-flow margin
10% net margin · 13% ROE
Interest covered 19.0×
Model-based scoring. For information only — not financial advice.
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.90B, and a P/E ratio of 17.0x.
The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.